EMA Issues Guidance on 3D Printing for Oral Drug Manufacturing

The European Medicines Agency has released new guidance to support the use of 3D printing (3DP), or additive manufacturing, in producing solid oral dosage forms. The document highlights how this technology enables layer-by-layer fabrication of medicines using digital models, offering flexibility and innovation in pharmaceutical production.

A major advantage of 3DP is its ability to enable personalised, patient-centric medicines. It allows customisation of dosage strength, shape, flavour, and drug combinations—benefiting populations such as children, the elderly, and patients with complex or rare conditions. The technology also supports small-scale, efficient manufacturing with automated workflows.

The guidance outlines key quality considerations, including material properties, formulation printability, and the impact on critical quality attributes like content uniformity and dissolution. Special attention is given to “pharma inks,” intermediate materials whose stability and consistency must be ensured.

As a non-standard process, 3DP requires robust validation, risk assessment, and compliance with GMP standards. The EMA also encourages advanced monitoring tools to maintain consistent quality and ensure safe, effective products.

04-05-2026